CSL shares crashed after a US$5 billion impairment warning and weaker guidance shocked investors, sending the stock below A$100. Despite strong long-term fundamentals in plasma therapies, technical indicators remain bearish with heavy selling pressure still dominating the chart.
Elevra Lithium has surged over 400% amid stronger lithium prices, record revenue, and growing EV demand. Backed by North America’s largest hard-rock lithium mine, ELV remains technically bullish, with investors closely watching a breakout above A$14.20.
Fortescue (ASX: FMG) shares have rebounded on stronger iron ore prices, improving Chinese demand and solid shipments. Sentiment is also lifted by dividends and production strength, while its green energy transition and decarbonisation plans support long-term growth above A$20 momentum.
We continue to view Accent Group (AX1) as one of the few genuinely scaled, defensible retail platforms in Australia and New Zealand. In a sector where earnings volatility is the norm and brand power often trumps execution, AX1 stands out because it has quietly built a multi-brand ecosystem that gives it pricing control, data-driven consumer reach, and operational leverage that smaller retailers simply cannot replicate.
Bega Group has evolved from a regional dairy co-operative into a diversified branded food business spanning cheese, spreads and milk beverages, combining defensive staple demand with branded exposure. The investment case now hinges on whether recent operational improvements can translate scale and strong household brands into sustained margin and ROIC expansion. However, with limited product innovation and rising marketing spend largely aimed at defending shelf space, the company’s growth profile remains more defensive than structurally transformative.
If you bought Neuren Pharmaceuticals (ASX: NEU) near its peak, the recent volatility has been uncomfortable. Despite having its first approved drug for a rare paediatric disorder, growing royalty income and a promising pipeline, the share price has repeatedly rallied and retraced over the past two years. The key question now is whether NEU has already formed a durable bottom — or if another leg down could still test investor conviction.
